{
  "source": "Global Wire",
  "source_name": "Global Wire",
  "meta_source_name": "Global Wire",
  "source_guid": "src-global-wire",
  "trust_level": 10,
  "source_type": "NEWS_WIRE",
  "group_guid": "group-simulation",
  "event_type": "MACRO_DATA",
  "published_at": "2026-02-22T04:34:21.227967",
  "upload_as_group": "group-simulation",
  "title": "Update regarding Vitality Pharma",
  "story_body": "Vitality Pharma (VIT) is among multiple pharmaceutical companies affected by a widespread supply chain disruption impacting the healthcare industry. As of 09:00 EST, industry reports confirm that a shortage of critical active pharmaceutical ingredients (APIs) has resulted in production delays and stockpile depletion.\n\nThe shortage, triggered by a combination of manufacturing capacity constraints and logistical bottlenecks, is affecting several major healthcare companies. Vitality Pharma (VIT), a leading developer and manufacturer of specialty pharmaceuticals, has confirmed that its operations are among those impacted.\n\nAccording to industry sources, the shortage is expected to persist for an estimated 6-8 weeks, with potential longer-term effects on the global pharmaceutical supply chain. The disruption has prompted regulatory agencies and industry associations to convene emergency meetings to discuss mitigation strategies and potential solutions.\n\nVitality Pharma (VIT) has issued a statement acknowledging the shortage and assuring stakeholders that the company is working closely with suppliers, distributors, and regulatory authorities to minimize the impact on its operations and customers. The company has not provided a detailed timeline for resolution or specified the extent of the disruption on its production levels.\n\nThe current shortage serves as a reminder of the healthcare industry's vulnerability to supply chain disruptions and highlights the need for enhanced risk management and contingency planning. As the situation continues to unfold, industry observers will be closely monitoring the responses of affected companies, including Vitality Pharma (VIT), and the broader sector's efforts to address the shortage and prevent similar disruptions in the future.",
  "validation_metadata": {
    "scenario": "Supply Chain Ripple",
    "base_ticker": "VIT",
    "expected_tier": "SILVER",
    "expected_event": "MACRO_DATA",
    "expected_relevant_clients": [
      "550e8400-e29b-41d4-a716-446655440001",
      "550e8400-e29b-41d4-a716-446655440005"
    ],
    "relationship_hops": 0,
    "expected_feed_rank_range": "1-50",
    "validation_rules": {
      "min_score": 50,
      "max_score": 74,
      "expected_tier": "SILVER",
      "must_match_event": false,
      "expected_event": "MACRO_DATA",
      "expected_entities": [],
      "expected_relevant_clients": [],
      "relationship_hops": 0,
      "expected_feed_rank_range": "1-50"
    }
  }
}